AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference
May 19 2022 - 7:00AM
AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or
the “Company”), an immuno-pharma company focused on the research
and development of therapeutics to treat multiple types of cancers,
immune disorders, and viral diseases, including COVID-19, the
disease caused by the SARS-CoV-2 virus, today announced that Thomas
K. Equels, M.S. J.D., Chief Executive Officer of AIM, will present
at the H.C. Wainwright Global Investment Conference being held May
23-26, 2022 in Miami, FL and virtually.
In addition to the presentation, management will
be available to participate in virtual one-on-one meetings with
qualified members of the investor community who are registered to
attend the conference. For more information, please visit the
conference website.
A video webcast of the presentation will be
accessible for viewing on-demand beginning on Tuesday, May 24,
2022, at 7:00 AM ET for those registered for the event and will be
available on the Events page in the Investor Relations section of
the Company’s website (aimimmuno.com). The webcast replay will be
archived for 90 days following the event.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immune-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders, and viral diseases,
including COVID-19. The Company’s lead product, Ampligen®
(rintatolimod) is an immuno-modulator with broad spectrum activity
being developed for globally important cancers, viral diseases and
disorders of the immune system.
Ampligen is currently being used as a
monotherapy to treat pancreatic cancer patients in an Early Access
Program (EAP) approved by the Inspectorate of Healthcare in the
Netherlands at Erasmus Medical Center and AIM plans to initiate a
Phase 2 clinical study in 2022. The Company also has multiple
ongoing clinical trials to evaluate Ampligen as a combinational
therapy for the treatment of a variety of solid tumor types both
underway and planned at major cancer research centers.
Additionally, Ampligen is approved in Argentina for the treatment
of Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and
is currently being evaluated for SARS-CoV-2 and COVID-19 Long
Hauler.
For more information, please visit aimimmuno.com
and connect with the Company on Twitter, LinkedIn, and
Facebook.
Investor Relations ContactJTC
Team, LLCJenene Thomas 833-475-8247AIM@jtcir.com
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Apr 2024 to May 2024
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From May 2023 to May 2024